To see all protocols that comply with the WHO Essential Medicine List 

This protocol has been superseded due to teniposide no longer being available in Australia. Primary CNS lymphoma (PCNSL) MATRix (methotrexate cytarabine thiotepa and rituximab) is the preferred regimen.

 Teniposide drug supply:

Teniposide was removed from the Australian Register of Therapeutic Goods (ARTG) in June 2017 as global production was ceased. Access to teniposide may still be available via the Special Access Scheme

Patients with lymphoma should be considered for inclusion into clinical trials. Link to ALLG websiteANZCTR website and Lymphoma Australia website.

This protocol is based on limited evidence; refer to the evidence section of this protocol for more information.

The information contained in this protocol is based on the highest level of available evidence and consensus of the eviQ reference committee regarding their views of currently accepted approaches to treatment. Any clinician (medical oncologist, haematologist, radiation oncologist, medical physicist, radiation therapist, pharmacist or nurse) seeking to apply or consult this protocol is expected to use independent clinical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. While eviQ endeavours to link to reliable sources that provide accurate information, eviQ and the Cancer Institute NSW do not endorse or accept responsibility for the accuracy, currency, reliability or correctness of the content of linked external information sources. Use is subject to eviQ’s disclaimer available at

Send feedback for this page

First approved:
Last reviewed:
Review due:

The currency of this information is guaranteed only up until the date of printing, for any updates please check:

05 Jul 2022